Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23874343 | 1.00 | SSTR4 (0.36) | SSTR4BACE1BACE2HDAC1HDAC8 | |
| SCHEMBL2844180 | 0.83 | MTNR1A (0.34) | SSTR4PDPK1CCR1AAK1 | |
| SCHEMBL30218195 | 0.80 | BACE1 (0.35) | SSTR4BACE1BACE2HTR2AHTR2C | |
| SCHEMBL23874559 | 0.80 | BACE1 (0.35) | SSTR4BACE1BACE2HTR2AHTR2C | |
| SCHEMBL22175746 | 0.76 | SSTR4 (0.40) | SSTR4BACE1BACE2HTR2AHTR2C | |
| SCHEMBL30908598 | 0.75 | GRM2 (0.40) | SSTR4HDAC1HDAC8HDAC6PDPK1 | |
| SCHEMBL960170 | 0.75 | SSTR4 (0.34) | SSTR4HDAC1HDAC8HDAC6HTR2C | |
| SCHEMBL2033422 | 0.72 | HDAC1 (0.37) | SSTR4HDAC1HDAC8HDAC6PDPK1 | |
| SCHEMBL14480026 | 0.72 | SSTR4 (0.33) | SSTR4HTR2CSLC6A4AKT1 | |
| SCHEMBL25381711 | 0.72 | AKT1 (0.37) | SSTR4HDAC1HTR2CSLC6A4GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528815-B2 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | NXERA PHARMA UK LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| CN-115867280-B | 5-Amino-8- (4-pyridyl) - [1,2,4] triazolo [4,3-C ] pyrimidin-3-one compounds for anticancer use | 奈克斯拉制药英国有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20230146483-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | NXERA PHARMA UK LIMITED (GB) | 2023-05-11 | — | — | US | disclosed |
| CN-115867280-A | 5-amino-8- (4-pyridinyl) - [1,2,4] triazolo [4,3-C ] pyrimidin-3-one compounds for use in cancer therapy | 赫普泰雅治疗有限公司 | 2023-03-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146483-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | ADORA2A, ADORA1, ADORA3 | SSTR4 761/4885BACE1 3245/4885BACE2 3754/4885 |
| US-12528815-B2 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | ADORA1, ADORA3, OPRL1 | SSTR4 523/4885BACE1 3809/4885BACE2 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.